Loader

Pathways

PathWhiz ID Pathway Meta Data

PW132600

Pw132600 View Pathway
metabolic

Oteracil Drug Metabolism

Homo sapiens
Oteracil is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Oteracil passes through the liver and is then excreted from the body mainly through the kidney.

PW145529

Pw145529 View Pathway
drug action

Oteracil Drug Metabolism Action Pathway

Homo sapiens

PW127398

Pw127398 View Pathway
drug action

Oteseconazole Action Pathway

Homo sapiens
Oteseconazole is an azole antifungal used to prevent recurrent vulvovaginal candidiasis in females who are not of reproductive potential. By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC). Oteseconazole has demonstrated activity against Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida lusitaniae and Candida dubliniensis. Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and little interaction with human cytochrome P450s. Oteseconazole inhibits the enzyme lanosterol 14-alpha demethylase. Lanosterol 14-alpha demethylase is the enzyme that catalyzes the synthesis of 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol from lanosterol. With this enzyme inhibited ergosterol synthesis cannot occur which causes a significant low concentration of ergosterol in the fungal cell. Ergosterol is essential in maintaining membrane integrity in fungi. Without ergosterol, the fungus cell cannot synthesize membranes thereby increasing fluidity and preventing growth of new cells. This leads to cell lysis which causes it to collapse and die.Because of its ability to bind and inhibit CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC). Besides blocking the formation of ergosterol, oteseconazole also promotes the accumulation of 14-methylated sterols that lead to fungal cell death.

PW146577

Pw146577 View Pathway
drug action

Oteseconazole Drug Metabolism Action Pathway

Homo sapiens

PW176109

Pw176109 View Pathway
metabolic

Oteseconazole Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Oteseconazole are predicted with biotransformer.

PW145183

Pw145183 View Pathway
drug action

Ouabain Drug Metabolism Action Pathway

Homo sapiens

PW123588

Pw123588 View Pathway
disease

Ovarian Cancer

Homo sapiens

PW120522

Pw120522 View Pathway
signaling

OX40 Signaling Pathway

Homo sapiens
OX40 is a type 1 transmembrane glycoprotein, reported nearly 30 years ago as a cell surface antigen expressed on activated T cells. Since its discovery, it has been validated as a bone fide costimulatory molecule for T cells and member of the TNF receptor family. Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a fellow of the TNFR-superfamily of receptors. It is a protein which in humans is encoded by the TNFRSF4 gene which contains 9 exons. It also has been demonstrated to have a key role in the survival and homeostasis of effector and memory T cells in transplantation and autoimmunity. OX40 is not constitutively expressed on resting naive T cells, unlike CD28. As a secondary co-stimulatory immune checkpoint molecule, it expresses after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells and resting naive T cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell and the expression of CD28; without CD28, expression of OX40 is delayed and of fourfold lower levels.

PW127494

Pw127494 View Pathway
drug action

Oxacillin Action Pathway

Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Oxacillin is a penicillin antibiotic used to treat a number of susceptible bacterial infections. Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor.

PW144825

Pw144825 View Pathway
drug action

Oxacillin Drug Metabolism Action Pathway

Homo sapiens